"The rheumatologists at Duke Rheumatology Clinic - Clinic 1J deliver comprehensive and aggressive care to patients with a wide range of autoimmune diseases including rheumatoid arthritis, gout, systemic lupus erythematosus, fibromyalgia and scleroderma. Each treatment plan is tailored to fit the individual patient's needs and lifestyle."

During the past decade, Duke University Medical Center: Division of Rheumatology and Immunology conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Duke University Medical Center: Division of Rheumatology and Immunology" #1 collaborator was "Immune Tolerance Network (ITN)" with 2 trials as a collaborator, "Rho Federal Systems Division, Inc." with 2 trials as a collaborator, "Autoimmunity Centers of Excellence" with 1 trials as a collaborator, "PPD" with 1 trials as a collaborator and "Seagen Inc." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Duke University Medical Center: Division of Rheumatology and Immunology" are "Diffuse Cutaneous Systemic Sclerosis" (1 trials), "Juvenile Dermatomyositis (JDM)" (1 trials), "Juvenile Idiopathic Arthritis (JIA)" (1 trials), "Multiple Sclerosis (MS)" (1 trials) and "Pediatric SLE" (1 trials). Many other conditions were trialed in "Duke University Medical Center: Division of Rheumatology and Immunology" in a lesser frequency.

Most popular intervention types in "Duke University Medical Center: Division of Rheumatology and Immunology" are "Biological" (2 trials) and "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Ad26.COV2.S" (1 trials), "BNT162b2" (1 trials), "BNT162b2, Bivalent" (1 trials), "Brentuximab Vedotin" (1 trials) and "Continue IS (B cell depletion therapy)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Duke University Medical Center: Division of Rheumatology and Immunology" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Duke University Medical Center: Division of Rheumatology and Immunology". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Duke University Medical Center: Division of Rheumatology and Immunology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Duke University Medical Center: Division of Rheumatology and Immunology, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".